| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
12,970,000 |
| Market
Cap: |
641.37(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$10.17 - $49.33 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 6.6 |
| Insider 6 Months : 6.6 |
| Insider 3/6 Months : 13.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cidara Therapeutics is a biotechnology company focused on the discovery, development and commercialization of therapeutics designed for patients facing diseases. Co. is focused on infectious diseases and oncology. Co.'s primary product candidate is rezafungin acetate, an intravenous formulation of an echinocandin antifungal. Rezafungin is being developed as a once-weekly therapy for the first-line treatment and prevention of invasive fungal infections. In addition, Co. is using its Cloudbreak® platform to develop a potential new class of drugs called drug-Fc Conjugates, which target respiratory syncytial virus, human immunodeficiency virus, and the SARS-CoV-2 strains causing COVID-19.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
3,320 |
3,320 |
3,320 |
71,320 |
| Total Buy Value |
$73,895 |
$73,895 |
$73,895 |
$237,160 |
| Total People Bought |
1 |
1 |
1 |
3 |
| Total Buy Transactions |
2 |
2 |
2 |
5 |
| Total Shares Sold |
0 |
3,437 |
5,270 |
123,627 |
| Total Sell Value |
$0 |
$75,482 |
$96,814 |
$186,450 |
| Total People Sold |
0 |
2 |
3 |
4 |
| Total Sell Transactions |
0 |
2 |
4 |
10 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mineo Chrysa |
Director |
– • – |
2025-06-03 |
4 |
B |
$23.44 |
$24,614 |
D/D |
1,050 |
3,320 |
2.39 |
106% |
|
| Mineo Chrysa |
Director |
– • – |
2025-06-02 |
4 |
B |
$21.71 |
$49,281 |
D/D |
2,270 |
2,270 |
2.39 |
112% |
|
| Davarpanah Nicole Negar |
Chief Medical OfficerOfficer |
• – – |
2025-05-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,692 |
|
121% |
|
| Davarpanah Nicole Negar |
Chief Medical Officer |
• – – |
2025-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
31,692 |
|
- |
|
| Ward Shane |
COO & CLO |
• – – |
2025-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
39,674 |
|
- |
|
| Ward Shane |
COO & CLO |
• – – |
2025-03-11 |
4 |
S |
$21.96 |
$36,542 |
D/D |
(1,664) |
14,674 |
|
-129% |
|
| Tari Leslie |
CHIEF SCIENTIFIC OFFICER |
• – – |
2025-03-11 |
4 |
S |
$21.96 |
$38,940 |
D/D |
(1,773) |
16,215 |
|
-129% |
|
| Karbe Frank |
Chief Financial Officer |
• – – |
2025-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
57,500 |
57,500 |
|
- |
|
| Shah Rajeev M. |
Director |
– • – |
2024-11-26 |
4 |
A |
$14.91 |
$5,811,445 |
I/I |
389,716 |
1,092,796 |
|
- |
|
| Sandison Taylor |
Chief Medical Officer |
• – – |
2024-09-11 |
4 |
S |
$11.64 |
$10,752 |
D/D |
(924) |
23,067 |
|
-89% |
|
| Tari Leslie |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-09-11 |
4 |
S |
$11.64 |
$10,580 |
D/D |
(909) |
17,788 |
|
-89% |
|
| Shah Rajeev M. |
Director |
– • – |
2024-07-19 |
4 |
A |
$0.00 |
$0 |
I/I |
703,080 |
703,080 |
|
- |
|
| Stein Jeffrey |
President & CEO |
• • – |
2024-06-07 |
4 |
B |
$13.21 |
$105,680 |
I/I |
8,000 |
24,580 |
2.66 |
-13% |
|
| Shah Preetam |
CFO & CBO |
• – – |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
108,750 |
335,960 |
|
- |
|
| Tari Leslie |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
111,250 |
369,931 |
|
- |
|
| Ward Shane |
COO & CLO |
• – – |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
120,000 |
318,770 |
|
- |
|
| Sandison Taylor |
Chief Medical Officer |
• – – |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
128,750 |
475,845 |
|
- |
|
| Ward Shane |
COO & CLO |
• – – |
2024-03-11 |
4 |
S |
$0.67 |
$13,713 |
D/D |
(20,473) |
198,770 |
|
11% |
|
| Stein Jeffrey |
President & CEO |
• • – |
2024-03-11 |
4 |
D |
$0.69 |
$39,117 |
D/D |
(56,692) |
1,153,693 |
|
- |
|
| Sandison Taylor |
Chief Medical Officer |
• – – |
2024-03-11 |
4 |
S |
$0.67 |
$13,839 |
D/D |
(20,662) |
347,095 |
|
11% |
|
| Tari Leslie |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-03-11 |
4 |
S |
$0.67 |
$14,085 |
D/D |
(21,029) |
258,681 |
|
11% |
|
| Shah Preetam |
CFO & CBO |
• – – |
2024-03-11 |
4 |
S |
$0.67 |
$12,680 |
D/D |
(18,931) |
227,210 |
|
11% |
|
| Sandison Taylor |
Chief Medical Officer |
• – – |
2023-09-11 |
4 |
S |
$0.95 |
$17,810 |
D/D |
(18,793) |
363,757 |
|
26% |
|
| Tari Leslie |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-09-11 |
4 |
S |
$0.95 |
$17,509 |
D/D |
(18,469) |
275,710 |
|
26% |
|
| Tari Leslie |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-08-14 |
4 |
B |
$0.97 |
$9,700 |
D/D |
10,000 |
294,179 |
2.74 |
-18% |
|
127 Records found
|
|
Page 1 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
1.42 (2.96%) 
